Fifth Third Bancorp Decreases Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Fifth Third Bancorp lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 74.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 604 shares of the company's stock after selling 1,760 shares during the period. Fifth Third Bancorp's holdings in Medpace were worth $201,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. McGuire Investment Group LLC boosted its stake in shares of Medpace by 1.1% in the 4th quarter. McGuire Investment Group LLC now owns 44,665 shares of the company's stock valued at $14,839,000 after purchasing an additional 472 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in Medpace by 28.1% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 15,543 shares of the company's stock valued at $5,164,000 after purchasing an additional 3,410 shares during the last quarter. Lifestyle Asset Management Inc. boosted its position in Medpace by 6.0% in the fourth quarter. Lifestyle Asset Management Inc. now owns 3,917 shares of the company's stock valued at $1,301,000 after buying an additional 220 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in Medpace by 562.3% during the fourth quarter. Janney Montgomery Scott LLC now owns 54,761 shares of the company's stock worth $18,193,000 after buying an additional 46,493 shares during the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of Medpace by 967.4% during the fourth quarter. SG Americas Securities LLC now owns 24,593 shares of the company's stock worth $8,171,000 after buying an additional 22,289 shares in the last quarter. Institutional investors own 77.98% of the company's stock.

Medpace Trading Up 1.0 %

Shares of MEDP traded up $3.60 during trading hours on Tuesday, reaching $346.98. 204,655 shares of the stock traded hands, compared to its average volume of 211,925. The company has a market cap of $10.78 billion, a price-to-earnings ratio of 30.38, a PEG ratio of 1.79 and a beta of 1.36. The stock has a fifty day simple moving average of $342.61 and a 200 day simple moving average of $350.79. Medpace Holdings, Inc. has a 52 week low of $291.15 and a 52 week high of $459.77.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Baird R W cut Medpace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 23rd. Truist Financial lowered their target price on shares of Medpace from $415.00 to $397.00 and set a "hold" rating for the company in a report on Monday, October 14th. William Blair reaffirmed an "outperform" rating on shares of Medpace in a research note on Tuesday, October 22nd. Robert W. Baird raised their price objective on Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research note on Monday, January 27th. Finally, Redburn Atlantic initiated coverage on shares of Medpace in a report on Monday, October 14th. They set a "buy" rating and a $404.00 target price on the stock. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.